Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Immunosuppression Drug Weaning in Liver Recipients Exhibiting Biomarkers of High Likelihood of Tolerance

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Liver transplant recipients with at least 3 years of post-operative follow-up in whom gene expression pattern changed from non-tolerant to tolerant under sirolimus treatment.~2. Feasibility of performing very frequent (every 2-3 weeks) clinical follow-up visits.~3. No history of graft rejection during the previous 12 months.~4. Basal liver biopsy without signs of rejection~5. Stability of liver graft function, defined as: a) normal liver function tests (AST, ALT, ALP, GGT) during at least 6 months; or alternatively b) minor alterations in liver function tests that have not changed over the previous 6 months (AST/ALT \< 2 fold normal levels; ALP \< 1.5 fold normal levels; GGT \< 2 fold normal levels; bilirubin \< 2 mg/dL).~6. Presence of peripheral blood biomarkers of high likelihood of tolerance as defined by: a) transcriptional pattern associated with tolerance regardless of the basal immunosuppressive regimen; and/or b) 2-fold increase in Treg frequency in patients who have discontinued calcineurin inhibitors in the 12 months prior to inclusion.~7. Signature of informed consent.~Exclusion Criteria:~1. Requirement of immunosuppressive treatment for an indication different to liver transplantation.~2. Documented human immunodeficiency virus (HIV) infection.~3. Liver-Kidney transplant recipients.~4. History of liver autoimmune disease (autoimmune hepatitis, primary liver cirrhosis, primary sclerosing cholangitis)~5. Active hepatitis C virus infection as defined by positive serum HCV-RNA.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Weaning patients (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).